Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23893
Title: Sleep-disordered breathing does not impact maternal outcomes in women with hypertensive disorders of pregnancy.
Austin Authors: Wilson, Danielle L ;Howard, Mark E ;Fung, Alison M;O'Donoghue, Fergal J ;Barnes, Maree ;Lappas, Martha;Walker, Susan P
Affiliation: Institute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia
Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia
Issue Date: 27-Apr-2020
metadata.dc.date: 2020-04-27
Publication information: PLoS One 2020; 15(4): e0232287
Abstract: Sleep-disordered breathing (SDB) is characterised by intermittent hypoxemia, sympathetic activation and widespread endothelial dysfunction, sharing pathophysiologic features with the hypertensive disorders of pregnancy. We sought to determine whether coexisting SDB would adversely impact the outcomes of women with gestational hypertension (GH) and preeclampsia (PE), and healthy matched controls. Women diagnosed with GH or PE along with BMI- and gestation-matched normotensive controls underwent polysomnography in late pregnancy to establish the presence or absence of SDB (RDI ≥ 5). Clinical outcomes of hypertensive disease severity were compared between groups, and venous blood samples were taken in the third trimester and at delivery to examine for any impact of SDB on the anti-angiogenic markers of PE. Data was available for 17 women with PE, 24 women with GH and 44 controls. SDB was diagnosed in 41% of the PE group, 63% of the GH group and 39% of the control group. Women with PE and co-existing SDB did not have worse outcomes in terms of gestation at diagnosis of PE (SDB = 29.1 (25.9, 32.1) weeks vs. no SDB = 32.0 (29.0, 33.9), p = n.s.) and days between diagnosis of PE and delivery (SDB = 20.0 (4.0, 35.0) days vs. no SDB = 10.5 (9.0, 14.0), p = n.s.). There were also no differences in severity of hypertension, antihypertensive treatment and biochemical, haematological and anti-angiogenic markers of PE between SDB and no SDB groups. Similar results were observed among women with GH. Healthy control women with SDB were no more likely to develop a hypertensive disorder of pregnancy in the later stages of pregnancy (SDB = 5.9% vs. no SDB = 7.4%, p = n.s.). Increasing the threshold for diagnosis of SDB to RDI ≥ 15 did not unmask a worse prognosis. The presence of SDB during pregnancy did not worsen the disease course of GH or PE, and was not associated with high blood pressure or anti-angiogenic markers of hypertensive disease amongst healthy pregnant women. Given the numerous reports of the relationship between SDB and diagnosis of hypertensive disorders of pregnancy, it appears more work is required to distinguish causal, versus confounding, pathways.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23893
DOI: 10.1371/journal.pone.0232287
ORCID: 0000-0001-6754-7359
0000-0001-7772-1496
0000-0001-5099-3184
0000-0002-4744-6929
PubMed URL: 32339208
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Feb 25, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.